2 results
Approved WMORecruiting
To assess which treatment leads to the best patient outcome on the short term (1 year) and the long term (5 years)
Approved WMOWill not start
This study will evaluate the efficacy of brentuximab vedotin in combination with lenalidomide and rituximab among subjects with relapsed or refractory CD30-positive (CD30 expression >=1%) or CD30 <1% (CD30 expression <1%) DLBCL.